By contrast, in MS patients, treated with other immunomodulatory therapies (i.e., IFN-β), the most prevalent side effect is represented by euthyroid or hypothyroid autoimmune thyroiditis (26, 27, 40). This evidence concerns the gene IFNB1 and myeloid sarcoma.